Biogen Inc. shares BIIB, -3.78% slid 4% in premarket trade Wednesday, after the company said it had received a"negative trend vote" from an advisory committee to the European Medicines Agency for its Alzheimer's disease treatment aducanumab. The vote means that the committee was unable to agree to grant authorization to the treatment, which has already won approval from the U.S. Food and Drug Administration, in a decision deemed controversial.
"While we are disappointed with the trend vote, we strongly believe in the strength of our data and that aducanumab has the potential to make a positive and meaningful difference for people and families affected by Alzheimer's disease," said Priya Singhal, M.D., M.P.H., head of global safety & regulatory sciences and interim head of R&D at Biogen.
Biden even has a Alzheimer Disease drug? Cool